Arylamine N-acetyltransferase I

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 11, 2007, Pages 1999-2005

  Minchin, Rodney F ^a   Hanna, Patrick E ^b   Dupret, Jean Marie ^c   Wagner, Carston R ^b   Rodrigues Lima, Fernando ^c   Butcher, Neville J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Arylamine N acetyltransferase; Catalytic triad; Folate metabolism; Polymorphism; Ubiquitination

Indexed keywords

4 AMINOBENZOYLGLUTAMATE; AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; CYSTEINE PROTEINASE; FOLIC ACID; HYDRAZINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; UNCLASSIFIED DRUG;

ACETYLATION; ACETYLATOR PHENOTYPE; ANIMAL CELL; CATALYSIS; CHROMOSOME 8; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME SUBSTRATE; GENE; GENE EXPRESSION REGULATION; GENE LOCATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; MALE; NAT1 GENE; NONHUMAN; PROTEIN STABILITY; SEQUENCE HOMOLOGY; SHORT SURVEY; SPINA BIFIDA; UBIQUITINATION;

ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; CATALYSIS; DISEASE; GENOME, HUMAN; HUMANS; ISOENZYMES;

MAMMALIA;

EID: 34548100609     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2006.12.006     Document Type: Short Survey

References (46)

1. Adam P.J., Berry J., Loader J.A., Tyson K.L., Craggs G., Smith P., et al. Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol. Cancer Res. 1 (2003) 826-835
2. Al-Buheissi S.Z., Patel H.R., Meinl W., Hewer A., Bryan R.L., Glatt H., et al. N-Acetyltransferase and sulfotransferase activity in human prostate: Potential for carcinogen activation. Pharmacogenet. Genomics 16 (2006) 391-399
3. Barker D.F., Husain A., Neale J.R., Martini B.D., Zhang X., Doll M.A., et al. Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. Pharmacogenet. Genomics 16 (2006) 515-525
4. Blum M., Grant D.M., McBride W., Heim M., and Meyer U.A. Human arylamine N-acetyltransferase genes: Isolation, chromosomal localization, and functional expression. DNA Cell Biol. 9 (1990) 193-203
5. Boissy R.J., Watson M.A., Umbach D.M., Deakin M., Elder J., Strange R.C., et al. A pilot study investigating the role of NAT1 and NAT2 polymorphisms in gastric adenocarcinoma. Int. J. Cancer 87 (2000) 507-511
6. Butcher N.J., Arulpragasam A., Goh H.L., Davey T., and Minchin R.F. Genomic organization of human arylamine N-acetyltransferase type I reveals alternative promoters that generate different 5′-UTR splice variants with altered translational activities. Biochem. J. 387 (2005) 119-127
7. Butcher N.J., Arulpragasam A., and Minchin R.F. Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: A mechanism for the slow acetylator phenotype and substrate-dependent down-regulation. J. Biol. Chem. 279 (2004) 22131-22137
8. Butcher N.J., Ilett K.F., and Minchin R.F. Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol. Pharmacol. 57 (2000) 468-473
9. Butcher N.J., Tetlow N.L., Cheung C., Broadhurst G.M., and Minchin R.F. Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. Cancer Res. 67 (2007) 85-92
10. Cornish V.A., Pinter K., Boukouvala S., Johnson N., Labrousse C., Payton M., et al. Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene. Pharmacogenomics J. 3 (2003) 169-177
11. Delomenie C., Goodfellow G.H., Krishnamoorthy R., Grant D.M., and Dupret J.M. Study of the role of the highly conserved residues Arg9 and Arg64 in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis. Biochem. J. 323 (1997) 207-215
12. Dolled-Filhart M., Ryden L., Cregger M., Jirstrom K., Harigopal M., Camp R.L., et al. Classification of breast cancer using genetic algorithms and tissue microarrays. Clin. Cancer Res. 12 (2006) 6459-6468
13. Dupret J.M., Goodfellow G.H., Janezic S.A., and Grant D.M. Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2. Functional analysis of recombinant NAT1/NAT2 chimeras expressed in Escherichia coli. J. Biol. Chem. 269 (1994) 26830-26835
14. Dupret J.M., and Grant D.M. Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2. J. Biol. Chem. 267 (1992) 7381-7385
15. Dupret J.M., and Rodrigues-Lima F. Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases. Curr. Med. Chem. 12 (2005) 311-318
16. *) promoter. Gene Expr. 7 (1998) 13-24
17. Goodfellow G.H., Dupret J.M., and Grant D.M. Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem. J. 348 (2000) 159-166
18. Hein D.W. Molecular genetics and function of NAT1 and NAT2: Role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 506-507 (2002) 65-77
19. *10) in combination with slow N-acetyltransferase 2 acetylator genotypes in a pilot case-control study. Env. Mol. Mutagen. 40 (2002) 161-167
20. Hickman D., Pope J., Patil S.D., Fakis G., Smelt V., Stanley L.A., et al. Expression of arylamine N-acetyltransferase in human intestine. Gut 42 (1998) 402-409
21. Husain A., Barker D.F., States J.C., Doll M.A., and Hein D.W. Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). Pharmacogenetics 14 (2004) 397-406
22. Jensen L.E., Hoess K., Mitchell L.E., and Whitehead A.S. Loss of function polymorphisms in NAT1 protect against spina bifida. Hum. Genet. 120 (2006) 52-57
23. Jensen L.E., Hoess K., Whitehead A.S., and Mitchell L.E. The NAT1 C1095A polymorphism, maternal multivitamin use and smoking, and the risk of spina bifida. Birth Defects Res. A Clin. Mol. Teratol. 73 (2005) 512-516
24. Li D., Jiao L., Li Y., Doll M.A., Hein D.W., Bondy M.L., et al. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 27 (2006) 103-111
25. Lilla C., Verla-Tebit E., Risch A., Jager B., Hoffmeister M., Brenner H., et al. Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 99-107
26. Liu F., Zhang N., Zhou X., Hanna P.E., Wagner C.R., Koepp D.M., et al. Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation. J. Mol. Biol. 361 (2006) 482-492
27. Minchin R.F. Acetylation of p-aminobenzoylglutamate, a folic-acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells. Biochem. J. 307 (1995) 1-3
28. Minchin R.F., Kadlubar F.F., and Ilett K.F. Role of acetylation in colorectal-cancer. Mutat. Res. 290 (1993) 35-42
29. Morton L.M., Schenk M., Hein D.W., Davis S., Zahm S.H., Cozen W., et al. Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenet. Genomics 16 (2006) 537-545
30. Pacifici G.M., Bencini C., and Rane A. Acetyltransferase in humans: Development and tissue distribution. Pharmacology 32 (1986) 283-291
31. Qin L.X. Chromosomal aberrations related to metastasis of human solid tumors. World J. Gastroenterol. 8 (2002) 769-776
32. Riddle B., and Jencks W.P. Acetyl-coenzyme A: Arylamine N-acetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituents on the rate. J. Biol. Chem. 246 (1971) 3250-3258
33. Ring B.Z., Seitz R.S., Beck R., Shasteen W.J., Tarr S.M., Cheang M.C., et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J. Clin. Oncol. 24 (2006) 3039-3047
34. Rodrigues-Lima F., Cooper R.N., Goudeau B., Atmane N., Chamagne A.M., Butler-Browne G., et al. Skeletal muscles express the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase. J. Histochem. Cytochem. 51 (2003) 789-796
35. Rodrigues-Lima F., Delomenie C., Goodfellow G.H., Grant D.M., and Dupret J.M. Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: Evidence for the conservation of a cysteine protease catalytic domain and an active-site loop. Biochem. J. 356 (2001) 327-334
36. Sim E., Pinter K., Mushtaq A., Upton A., Sandy J., Bhakta S., et al. Arylamine N-acetyltransferases: A pharmacogenomic approach to drug metabolism and endogenous function. Biochem. Soc. Trans. 31 (2003) 615-619
37. Sinclair J.C., Sandy J., Delgoda R., Sim E., and Noble M.E. Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nat. Struct. Biol. 7 (2000) 560-564
38. Smolen T., Brewer J., and Weber W. Testosterone modulation of N-acetylation in mouse kidney. J. Pharmacol. Exp. Ther. 264 (1993) 854-858
39. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 10869-10874
40. Stanley L.A., Coroneos E., Cuff R., Hickman D., Ward A., and Sim E. Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J. Histochem. Cytochem. 44 (1996) 1059-1067
41. Sugamori K.S., Wong S., Gaedigk A., Yu V., Abramovici H., Rozmahel R., et al. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice. Mol. Pharmacol. 64 (2003) 170-179
42. Varzim G., Monteiro E., Silva R., Pinheiro C., and Lopes C. Polymorphisms of arylamine N-acetyltransferase (NAT1 and NAT2) and larynx cancer susceptibility. ORL J. Otorhinolaryngol. Relat. Spec. 64 (2002) 206-212
43. Wang H., Liu L., Hanna P.E., and Wagner C.R. Catalytic mechanism of hamster arylamine N-acetyltransferase 2. Biochemistry 44 (2005) 11295-11306
44. Wang H., Vath G.M., Gleason K.J., Hanna P.E., and Wagner C.R. Probing the mechanism of hamster arylamine N-acetyltransferase 2 acetylation by active site modification, site-directed mutagenesis, and pre-steady state and steady state kinetic studies. Biochemistry 43 (2004) 8234-8246
45. Williams J.A., Stone E.M., Fakis G., Johnson N., Cordell J.A., Meinl W., et al. N-Acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast. Pharmacogenetics 11 (2001) 373-388
46. Zhang N., Liu L., Liu F., Wagner C.R., Hanna P.E., and Walters K.J. NMR-based model reveals the structural determinants of mammalian arylamine N-acetyltransferase substrate specificity. J. Mol. Biol. 363 (2006) 188-200